- Home
- EMD vs CTMX Comparison
EMD vs CTMX Comparison
Compare EMD & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMD | CTMX |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 626.6M | 642.2M |
| IPO Year | 2003 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EMD | CTMX |
|---|---|---|
| Price | $10.70 | $3.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $12.10 |
| AVG Volume (30 Days) | 163.3K | ★ 5.4M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.61 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.60 | $1.72 |
| 52 Week High | $11.30 | $8.21 |
Technical Indicators
Market Signals| Indicator | EMD | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management and long term investment company. The primary investment objective of the company is to seek high current income, and the secondary objective is to seek capital appreciation.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.